Valderílio Feijó Azevedo

Universidade Federal do Paraná

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Percival D. Sampaio‐Barros

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Célio Roberto Gonçalves

Universidade Unigranrio

Sueli Carneiro

Universidade do Estado do Rio de Janeiro

Antônio Carlos Ximenes

Instituto de Gastroenterologia de Goiânia

Mauro Waldemar Keiserman

Fundação Faculdade de Medicina

Rubens Bonfiglioli

Pontifícia Universidade Católica de Campinas

Sandra Lúcia Euzébio Ribeiro

Universidade Federal do Amazonas

Ivânio Alves Pereira

Universidade Federal de Santa Catarina

Washington A. Bianchi

Santa Casa de Misericórdia de Passos

Valéria Valim

Universidade Federal do Espírito Santo

Cooperative Institutions

Universidade Federal do Paraná

159

Red, Orange and Green Environmental Technologies (Brazil)

130

Center for Rheumatology

118

Universidade de São Paulo

102

Hospital de Clínicas Universidade Federal do Paraná

University College London

Universidade Federal de São Paulo

Universidade Federal do Espírito Santo

Pfizer (United States)

Universidade Federal de Minas Gerais

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry

RMD Open (2021)

Cláudia Diniz Lopes Marques Adriana María Kakehasi Marcelo Medeiros Pinheiro Lícia Maria Henrique da Mota Cleandro Pires de Albuquerque

Objectives To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. Methods Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. Results 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p<0.001) and pulse therapy with methylprednisolone (PR 1.38; 95% CI 1.14 to 1.67; p=0.001) remained significant; for hospitalisation, age >50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p<0.018). Conclusions Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process.

Immunosuppression

10.1136/rmdopen-2020-001461

Cite

Citations (67)

Lara D. Veeken (2013)

Morton Scheinberg Valderílio Feijó Azevedo

Biosimilar

10.1093/rheumatology/ket210

Cite

Citations (16)

Table of Contents

Value in Health Regional Issues (2012)

Carlos A Castañeda-Orjuela Hernando Díaz Nelson Alvis‐Guzmán Andrés Olarte Heidy Rodriguez

Table (database)

10.1016/s2212-1099(12)00080-5

Cite

Citations (0)

Epidemiologic profile of juvenile-onset compared to adult-onset spondyloarthritis in a large Brazilian cohort

Revista Brasileira de Reumatologia (English Edition) (2014)

Ângela Luzia Branco Pinto Duarte Cláudia Diniz Lopes Marques Adriana Bruscato Bortoluzzo Célio Roberto Gonçalves José Antonio Braga da Silva

To analyze the clinical and epidemiologic characteristics of juvenile-onset spondyloarthritis (SpA) (< 16 years) and compare them with a group of adult-onset (≥ 16 years) SpA patients. Prospective, observational and multicentric cohort with 1,424 patients with the diagnosis of SpA according to the European Spondyloarthropathy Study Group (ESSG) submitted to a common protocol of investigation and recruited in 29 reference centers participants of the Brazilian Registry of Spondyloarthritis (RBE – Registro Brasileiro de Espondiloartrites). Patients were divided in two groups: age at onset < 16 years (JOSpA group) and age at onset ≥ 16 years (AOSpA group). Among the 1,424 patients, 235 presented disease onset before 16 years (16.5%). The clinical and epidemiologic variables associated with JOSpA were male gender (p < 0.001), lower limb arthritis (p = 0.001), enthesitis (p = 0.008), anterior uveitis (p = 0.041) and positive HLA-B27 (p = 0.017), associated with lower scores of disease activity (Bath Ankylosing Spondylitis Disease Activity Index – BASDAI; p = 0.007) and functionality (Bath Ankylosing Spondylitis Functional Index – BASFI; p = 0.036). Cutaneous psoriasis (p < 0.001), inflammatory bowel disease (p = 0.023), dactylitis (p = 0.024) and nail involvement (p = 0.004) were more frequent in patients with adult-onset SpA. Patients with JOSpA in this large Brazilian cohort were characterized predominantly by male gender, peripheral involvement (arthritis and enthesitis), positive HLA-B27 and lower disease scores. Analisar as características clínicas e epidemiológicas da espondiloartrite (EspA) de início juvenil (< 16 anos) e compará-las com um grupo de pacientes com EspA de início na vida adulta (≥ 16 anos). Coorte prospectiva, observacional e multicêntrica com 1.424 pacientes com diagnóstico de EspA de acordo com o European Spondyloarthropathy Study Group (ESSG) submetidos a um protocolo comum de investigação e recrutados em 29 centros de referência participantes do Registro Brasileiro de Espondiloartrites (RBE). Os pacientes foram divididos em dois grupos: idade no início < 16 anos (grupo EspAiJ) e idade no início ≥ 16 anos. Entre os 1.424 pacientes, 235 manifestaram o início da doença antes dos 16 anos (16,5%). As variáveis clínicas e epidemiológicas associadas com a EspAiJ foram: gênero masculino (p < 0,001), artrite em membro inferior (p = 0,001), entesite (p = 0,008), uveíte anterior (p = 0,041) e HLA-B27 positivo (p = 0,017), em associação com escores mais baixos de atividade da doença (Bath Ankylosing Spondylitis Disease Activity Index – BASDAI; p = 0,007) e de capacidade funcional (Bath Ankylosing Spondylitis Functional Index – BASFI; p = 0,036). A psoríase cutânea (p < 0,001), a doença intestinal inflamatória (p = 0,023), a dactilite (p = 0,024) e o envolvimento ungueal (p = 0,004) foram mais frequentes em pacientes com EspA de início na vida adulta. Nessa grande coorte brasileira, os pacientes com EspAiJ se caracterizavam predominantemente pelo gênero masculino, envolvimento periférico (artrite e entesite), HLA-B27 positivo e escores de doença mais baixos.

Dactylitis

BASFI

Oligoarthritis

Spondyloarthropathy

Spondylitis

10.1016/j.rbre.2014.06.001

Cite

Citations (3)

Doença de Still do Adulto associada à neoplasia de ovário – relato de caso

Revista Brasileira de Reumatologia (2013)

Lilian Schade Scheila Fritsch Arthur Conelian Gentili Lúcia de Noronha Valderílio Feijó Azevedo

Relatamos um caso de diagnóstico de Doença de Still do Adulto (DSA) em paciente feminina com febre, mialgia, rash cutâneo fugaz e linfonodomegalia inguinal bilateral, após extensa investigação para exclusão de outras doenças reumatológicas, infecciosas e neoplásicas. A paciente inicialmente apresentou resposta ao tratamento com prednisona, porém evoluiu com aumento de volume de linfonodos inguinais, cuja biópsia revelou adenocarcinoma seroso de ovário. De acordo com nosso conhecimento, esse é o primeiro relato de neoplasia ovariana associada ao diagnóstico de DSA. We report a case of adult-onset Still's disease in a female patient with fever, myalgia, van- ishing rash and bilateral inguinal lymphadenopathy, diagnosed after extensive workup to exclude other rheumatic, infectious and neoplastic diseases. The patient initially respond- ed to corticosteroid therapy, but progressed to increased lymph nodes size that when biop- sied, revealed serous ovarian adenocarcinoma. To our knowledge, this is the first report of ovarian neoplasm associated with adult-onset Still's disease.

Inguinal lymphadenopathy

10.1016/j.rbr.2013.05.001

Cite

Citations (5)

Consenso Brasileiro de Espondiloartropatias: outras espondiloartropatias diagnóstico e tratamento - primeira revisão

Revista Brasileira de Reumatologia (2007)

Percival D. Sampaio‐Barros Valderílio Feijó Azevedo Rubens Bonfiglioli Wesley Ribeiro Campos Sueli Coelho da Silva Carneiro

Universidade Estadual de Campinas Faculdade de Ciencias Medicas Departamento de Clinica Medica

10.1590/s0482-50042007000400002

Cite

Citations (9)

Duloxetina no tratamento da dor lombar inflamatória crônica em pacientes portadores de espondilite anquilosante: relato de casos

DOAJ (DOAJ: Directory of Open Access Journals) (2011)

Valderílio Feijó Azevedo Varlei Serrato Marco Aurélio Azevedo Grande

Source

Cite

Citations (0)

A presença da reumatologia brasileira no GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis)

Revista Brasileira de Reumatologia (2011)

Cláudia Goldenstein‐Schainberg Roberto Ranza Rubens Bonfiglioli Sueli Carneiro Valderílio Feijó Azevedo

reumatoide sérico associado a intensa atividade infl amatória constituía uma condição clínica distinta da artrite reumatoide e da osteoartrite.

10.1590/s0482-50042011000500013

Cite

Citations (2)

Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review

Clinical and Experimental Rheumatology (2022)

Kevin Winthrop Yoshiya Tanaka Eun Bong Lee J. Wollenhaupt Ahmad Al Enizi

10.55563/clinexprheumatol/cpu6r9

Cite

Citations (18)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

RMD Open (2021)

Kurt de Vlam Alexis Ogdie Andrew G. Bushmakin Joseph C. Cappelleri Roy Fleischmann

Background Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib. Methods Data from two trials ( NCT01877668 ; NCT01882439 ) in patients receiving tofacitinib 5 mg twice daily, placebo switching to tofacitinib 5 mg twice daily at month 3 (placebo-to-tofacitinib) or adalimumab ( NCT01877668 only) were included. Improvement in pain (≥30%/≥50% decrease from baseline in Visual Analogue Scale pain score) was assessed; median time to initial (first post-baseline visit)/continued (first two consecutive post-baseline visits) pain improvement was estimated (Kaplan-Meier) for all treatment arms. A parametric model was used to determine the relationship between baseline pain severity and time to pain response in patients receiving tofacitinib. Results At month 3, more patients experienced pain improvements with tofacitinib/adalimumab versus placebo. Median days (95% CI) to initial/continued pain improvements of ≥30% and ≥50%, respectively, were 55 (29–57)/60 (57–85) and 85 (57–92)/171 (90–not estimable (NE)) for tofacitinib, versus 106 (64–115)/126 (113–173) and 169 (120–189)/NE (247–NE) for placebo-to-tofacitinib. Pain improvements were also experienced more quickly for adalimumab versus placebo. Predicted time to ≥30%/≥50% pain improvement was shorter in patients with higher baseline pain versus lower baseline pain (tofacitinib arm only). Conclusions In patients with PsA, pain improvements were experienced by more patients, and more rapidly, with tofacitinib and adalimumab versus placebo. In those receiving tofacitinib, higher baseline pain was associated with faster pain improvements.

10.1136/rmdopen-2021-001609

Cite

Citations (9)